NeoLAB® Solid Tumor Liquid Biopsy Testing
For any questions please contact our NeoGenomics’ Client Services at 866.776.5907, option 3 or email Client.Services@neogenomics.com.
Cell-free DNA analysis for solid tumor cancers
NeoLAB® Solid Tumor Liquid Biopsy is a next-generation sequencing assay for pan-cancer that includes 44 genes involved in solid tumor development and progression. This panel provides broad coverage of actionable markers supported by clinical guidelines and on-going clinical trials.
Biomarkers detected are implicated in a variety of tumor types including bladder, brain/CNS, breast, cervical, colorectal, endometrial, esophageal, gastric, head and neck, kidney, liver, lung, melanoma, ovarian, pancreatic, prostate, stomach, and thyroid.
- Identifying targetable alterations to guide treatment decision
- Monitoring disease status
- Detecting potential resistance to therapy and its cause
NeoLAB® Solid Tumor Liquid Biopsy detects >900 hotspot SNVs and indels across 44 genes
Genes Investigated in the NeoLAB® Solid Tumor Liquid Biopsy
Analytic validation demonstrated
Limit of Detection (LoD) = 0.1% allele fraction for indels, 0.15% for SNV.